The combination of EGCG with warfarin reduces deep vein thrombosis in rabbits through modulating HIF-1α and VEGF via the PI3K/AKT and ERK1/2 signaling pathways.
10.1016/S1875-5364(22)60172-9
- Author:
Yan LI
1
;
Jing-Ping GE
1
;
Ke MA
2
;
Yuan-Yuan YIN
1
;
Juan HE
1
;
Jian-Ping GU
3
Author Information
1. Department of Vascular and Interventional Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
2. Department of Acupuncture, Qinhuai District Hospital of Traditional Chinese Medicine, Nanjing 210000, China.
3. Department of Vascular and Interventional Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address: cjr.gujianping@vip.163.com.
- Publication Type:Randomized Controlled Trial, Veterinary
- Keywords:
Deep vein thrombosis;
EGCG;
ERK1/2;
HIF-1α;
PI3K/AKT;
VEGF;
Warfarin
- MeSH:
Animals;
Anticoagulants/pharmacology*;
Catechin/analogs & derivatives*;
Eosine Yellowish-(YS)/pharmacology*;
Fibrinogen/pharmacology*;
Hematoxylin/pharmacology*;
Human Umbilical Vein Endothelial Cells;
Humans;
Hydrogen Peroxide/pharmacology*;
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism*;
MAP Kinase Signaling System;
Phosphatidylinositol 3-Kinases/metabolism*;
Polyphenols/pharmacology*;
Proto-Oncogene Proteins c-akt/metabolism*;
RNA, Messenger;
Rabbits;
Rats;
Reactive Oxygen Species/metabolism*;
Signal Transduction;
Sincalide/pharmacology*;
Tea;
Thrombin/pharmacology*;
Vascular Endothelial Growth Factor A/metabolism*;
Venous Thrombosis/pathology*;
Warfarin/pharmacology*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(9):679-690
- CountryChina
- Language:English
-
Abstract:
Deep venous thrombosis (DVT) poses a major challenge to public health worldwide. Endothelial cell injury evokes inflammatory and oxidative responses that contribute to thrombus formation. Tea polyphenol (TP) in the form of epigallocatechin-3-gallate (EGCG) has anti-inflammatory and oxidative effect that may ameliorate DVT. However, the precise mechanism remains incompletely understood. The current study was designed to investigate the anti-DVT mechanism of EGCG in combination with warfarin (an oral anticoagulant). Rabbits were randomly divided into five groups. A DVT model of rats was established through ligation of the inferior vena cava (IVC) and left common iliac vein, and the animals were orally administered with EGCG, warfarin, or vehicle for seven days. In vitro studies included pretreatment of human umbilical vein endothelial cells (HUVECs) with different concentrations of EGCG for 2 h before exposure to hydrogen peroxide. Thrombus weight and length were examined. Histopathological changes were observed by hematoxylin-eosin staining. Blood samples were collected for detecting coagulation function, including thrombin and prothrombin times, activated partial thromboplastin time, and fibrinogen levels. Protein expression in thrombosed IVCs and HUVECs was evaluated by Western blot, immunohistochemical analysis, and/or immunofluorescence staining. RT-qPCR was used to determine the levels of AGTR-1 and VEGF mRNA in IVCs and HUVECs. The viability of HUVECs was examined by CCK-8 assay. Flow cytometry was performed to detect cell apoptosis and ROS generation was assessed by 2',7'-dichlorofluorescein diacetate reagent. In vitro and invivo studies showed that EGCG combined with warfarin significantly reduced thrombus weight and length, and apoptosis in HUVECs. Our findings indicated that the combination of EGCG and warfarin protects HUVECs from oxidative stress and prevents apoptosis. However, HIF-1α silencing weakened these effects, which indicated that HIF-1α may participate in DVT. Furthermore, HIF-1α silencing significantly up-regulated cell apoptosis and ROS generation, and enhanced VEGF expression and the activation of the PI3K/AKT and ERK1/2 signaling pathways. In conclusion, our results indicate that EGCG combined with warfarin modifies HIF-1α and VEGF to prevent DVT in rabbits through anti-inflammation via the PI3K/AKT and ERK1/2 signaling pathways.
